Deciphera begins Phase III of GIST candidate

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) began the Phase III INVICTUS trial of DCC-2618 to treat gastrointestinal stromal tumors (GIST).

The double-blind, U.S. study will enroll about 120 heavily pretreated fourth-line or greater patients to receive once-daily 150 mg oral DCC-2618 or placebo. The primary endpoint is median progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), time to tumor progression and overall survival (OS). ...